2022年3月6日简报:香港新增新冠肺炎确诊病例37529例,12岁以上人群首针新冠疫苗接种率达九成;韩国累计新冠肺炎确诊病例突破400万例

2022-03-06 MedSci整理 MedSci整理

截至北京时间2022年3月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿4509万例,新增1,344,487例,达到445,094,

截至北京时间2022年3月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过4亿4509万例,新增1,344,487例,达到445,094,654例。累计死亡病例601.4万例,达到6,014,656例。新增死亡为5,298例。康复为377,840,041例,重症和危重症病人达到72,438例;全球新冠确诊病例超过100万例的国家和地区达56个,124个国家和地区病例超10万例。昨日报道:2022年3月5日简报:香港新增新冠肺炎确诊病例52523例,死者九成未接种疫苗;全球重症新冠病人下降一年以来最低;国内数据显示奥密克戎重症发生率只有大约0.6%

香港12岁以上人群首针新冠疫苗接种率达九成

3月5日,香港特区政府公务员事务局局长聂德权表示,12岁以上人群首针新冠疫苗的接种率达到九成,接种人数超过606万。

聂德权表示,老年人接种率亦显著提升,80岁或以上人群接种率达51%,70至79岁逾78%,60至69岁逾88%。学童方面,3至11岁儿童接种率超过4成,12至19岁青年则逾9成。第二针新冠疫苗的接种率达78%。第三针的接种人数近200万。

他指出,接下来要聚焦推高“一老一幼”的接种率,提高第二针接种率到九成,加快第三针的接种。特区政府会继续投放更多资源,进一步推动老年人及儿童的接种安排,也让可以打第三针的市民能在最短时间内完成接种。

过去24小时,150名病人离世,年龄介于32岁至105岁,其中82人是养老院中的老人。

香港第五波疫情发生以来,已有1561起死亡病例,其中94.7%为年长者;91.3%未完成疫苗接种。在所有病例当中,完成两剂接种的,病死率为0.04%,未接种疫苗的,病死率为1.25%,高达前者的31倍。如果是80岁以上年长者未接种疫苗的,病死率更是高达8.6%;如果已接种两剂疫苗,病死率为1.57%。

今天通报的最年轻死者是32岁女性,已接种两剂科兴和一剂辉瑞/复必泰疫苗;2月28日快筛检测为阳性,出现发热症状;3月2日前去医院急诊室求医,住院之后出现心肌梗死症状,3月4日病逝。

香港新增新冠肺炎确诊病例37529例

香港特区政府卫生署卫生防护中心5日公布,截至当日零时,香港新增37529例新冠肺炎确诊病例。

据香港医管局介绍,过去24小时,再有150名确诊患者离世。

山东青岛一地新增44例新冠确诊

据青岛卫健委官网3月5日消息,2022年3月5日9时至20时,我市新增44例本土新冠肺炎确诊病例

韩国累计新冠肺炎确诊病例突破400万例

韩国3月5日报告累计新冠确诊病例突破400万例,单日新增死亡病例再创新高。韩国前一日新增确诊病例254327例,连续两天超过25万例,累计确诊超过421万例。韩国疾病管理厅说,韩国日增病例较一周前增长50%,累计确诊病例从突破300万例到超过400万例仅用时5天。

卫生部门预测,韩国日增病例或在3月中旬达到35万例峰值。

另外,韩国5日报告新增死亡病例216例,为疫情暴发以来最高,累计病亡8796人;现有重症病例896例,病床使用率为53.5%。韩国卫生部门预估,新冠重症病患数本月将升至2750人。

国家卫健委:3月4日新增新冠肺炎确诊病例281例 其中本土病例102例

国家卫生健康委员会5日通报,3月4日0-24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增新冠肺炎确诊病例281例。其中境外输入病例179例(广东79例,上海24例,福建16例,广西12例,天津11例,北京9例,山东9例,四川8例,河南3例,辽宁2例,浙江2例,吉林1例,江苏1例,重庆1例,甘肃1例),含16例由无症状感染者转为确诊病例(广东5例,四川5例,河南2例,广西2例,辽宁1例,浙江1例);本土病例102例(广东46例,其中东莞市24例、深圳市21例、惠州市1例;吉林19例,其中吉林市8例、延边朝鲜族自治州6例、长春市5例;内蒙古8例,其中呼和浩特市5例、呼伦贝尔市3例;河北6例,其中邢台市3例、石家庄市2例、保定市1例;山东5例,均在青岛市;天津3例,均在东丽区;上海3例,其中嘉定区2例、闵行区1例;广西3例,均在防城港市;海南2例,均在三亚市;云南2例,均在德宏傣族景颇族自治州;山西1例,在晋中市;黑龙江1例,在哈尔滨市;湖北1例,在武汉市;湖南1例,在怀化市;四川1例,在成都市),含9例由无症状感染者转为确诊病例(广东3例,广西3例,山西1例,海南1例,四川1例)。无新增死亡病例。新增疑似病例5例,均为境外输入病例(均在上海)。

当日新增治愈出院病例120例,解除医学观察的密切接触者5835人,重症病例较前一日减少4例。

境外输入现有确诊病例2166例(其中重症病例2例),现有疑似病例11例。累计确诊病例15189例,累计治愈出院病例13023例,无死亡病例。

截至3月4日24时,据31个省(自治区、直辖市)和新疆生产建设兵团报告,现有确诊病例3465例(其中重症病例14例),累计治愈出院病例102438例,累计死亡病例4636例,累计报告确诊病例110539例,现有疑似病例11例。累计追踪到密切接触者1673729人,尚在医学观察的密切接触者92578人。

31个省(自治区、直辖市)和新疆生产建设兵团报告新增无症状感染者166例,其中境外输入93例,本土73例(吉林24例,均在吉林市;广东18例,均在东莞市;上海16例,其中松江区6例、嘉定区5例、青浦区2例、黄浦区1例、普陀区1例、宝山区1例;云南8例,均在德宏傣族景颇族自治州;广西4例,其中防城港市3例、百色市1例;河北1例,在石家庄市;江苏1例,在南通市;湖北1例,在武汉市);当日转为确诊病例25例(境外输入16例);当日解除医学观察28例(境外输入25例);尚在医学观察的无症状感染者1500例(境外输入1049例)。

累计收到港澳台地区通报确诊病例190312例。其中,香港特别行政区169513例(出院21143例,死亡1554例),澳门特别行政区82例(出院79例),台湾地区20717例(出院13742例,死亡853例)。

奥密克戎在多国占比接近100%

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078682, encodeId=f5f420e868254, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat May 14 03:53:54 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258144, encodeId=a36b125814487, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334928, encodeId=135b1334928bf, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199863, encodeId=82af1199863a7, content=香港加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 06 10:45:40 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199810, encodeId=711d1199810fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sun Mar 06 07:01:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]
    2022-05-14 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078682, encodeId=f5f420e868254, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat May 14 03:53:54 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258144, encodeId=a36b125814487, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334928, encodeId=135b1334928bf, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199863, encodeId=82af1199863a7, content=香港加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 06 10:45:40 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199810, encodeId=711d1199810fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sun Mar 06 07:01:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078682, encodeId=f5f420e868254, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat May 14 03:53:54 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258144, encodeId=a36b125814487, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334928, encodeId=135b1334928bf, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199863, encodeId=82af1199863a7, content=香港加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 06 10:45:40 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199810, encodeId=711d1199810fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sun Mar 06 07:01:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078682, encodeId=f5f420e868254, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat May 14 03:53:54 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258144, encodeId=a36b125814487, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334928, encodeId=135b1334928bf, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199863, encodeId=82af1199863a7, content=香港加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 06 10:45:40 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199810, encodeId=711d1199810fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sun Mar 06 07:01:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]
    2022-03-06 carrotlyl

    香港加油

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2078682, encodeId=f5f420e868254, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat May 14 03:53:54 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258144, encodeId=a36b125814487, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334928, encodeId=135b1334928bf, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Mon Mar 07 21:53:54 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199863, encodeId=82af1199863a7, content=香港加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sun Mar 06 10:45:40 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199810, encodeId=711d1199810fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Sun Mar 06 07:01:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]
    2022-03-06 仁术2021

    不错,学习了。

    0

相关资讯

丹麦研究:感染过奥密克戎原始毒株 仍可能感染BA.2

BA.2亚型毒株是最早英国发现的奥密克戎毒株新变种,与BA.1是同属于“奥密克戎家族”的“表亲”。

2022年3月1日简报:香港新增新冠肺炎确诊病例34466例;韩国新增病例全球领先;全球疫情加速好转,美国疾控中心进一步放松口罩佩戴要求

截至北京时间2022年2月28日6时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿3679万例,新增933,209例,达到436,790,2

2022年3月3日简报:香港新增新冠肺炎确诊病例55353例;上海本土病例为奥密克戎变异株;新冠肺炎大流行导致全球焦虑和抑郁患病率增加25%

截至北京时间2022年3月3日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿4006万例,新增1,419,053例,达到440,060,

2022年3月2日简报:香港新增新冠肺炎确诊病例32597例;韩国疫情达顶峰;深圳此次奥密克戎感染人群中无重症和危重

截至北京时间2022年3月2日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿3834万例,新增1,192,408例,达到438,345,

2022年3月4日简报:香港新增新冠肺炎确诊病例56827例;全球累计因新冠死亡人数达600万;日本研究认为奥密克戎致死率比季节性流感高40%

截至北京时间2022年3月4日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿4174万例,新增1,446,505例,达到441,742,

2022年3月5日简报:香港新增新冠肺炎确诊病例52523例,死者九成未接种疫苗;全球重症新冠病人下降一年以来很低;国内数据显示奥密克戎重症发生率只有大约0.6%

截至北京时间2022年3月5日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿4369万例,新增1,630,768例,达到443,690,